Calamos International Growth A (CIGRX)
17.55
+0.10 (+0.57%)
USD |
Aug 12 2022
Returns Chart
Key Stats
Customize
| Expense Ratio | Total Assets Under Management | Dividend Yield | Turnover Ratio |
|---|---|---|---|
| 1.10% | 200.24M | 0.01% | 99.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized All Time Total Returns (Daily) | Max Drawdown (All) |
| -17.67M | -27.26% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks long-term capital growth. The fund normally invests at least 40% of its assets in securities of foreign issuers. It may invest in foreign securities that are represented in the United States securities markets by American Depositary Receipts ("ADRs") or similar depository arrangements. The fund may invest in securities of issuers in emerging markets to a significant extent. The investment adviser takes environmental, social and governance ("ESG") factors into account in making investment decisions. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | CIGIX |
| Equity Style | Large Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | International Equity |
| Broad Category | Equity |
| Category Name | Foreign Large Growth |
| Category Index | MSCI ACWI Ex USA Growth NR USD |
| Prospectus Objective | Foreign Stock |
| Fund Owner Firm Name | Calamos |
| Prospectus Benchmark Index | |
| MSCI EAFE Growth NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSACXUSNTR | 100.0% |
| Manager Tenure | |
| John Calamos | 17.39 yrs |
| John Hillenbrand | 17.39 yrs |
| Jon Vacko | 17.39 yrs |
| Dennis Cogan | 9.42 yrs |
| Nick Niziolek | 9.42 yrs |
| Eli Pars | 7.42 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
61
-17.67M
-8.248B
Category Low
5.213B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of July 31, 2022
Performance Versus Category
As of August 12, 2022. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of August 12, 2022.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
|
Novo Nordisk A/S Class B
|
4.50% | -- | -- |
|
Taiwan Semiconductor Manufacturing Co Ltd
|
3.99% | -- | -- |
|
ASML Holding NV
|
3.85% | -- | -- |
|
AIA Group Ltd
|
2.72% | -- | -- |
|
AstraZeneca PLC
|
2.39% | -- | -- |
|
Alcon Inc
|
2.39% | -- | -- |
|
LVMH Moet Hennessy Louis Vuitton SE
|
2.34% | -- | -- |
|
Sanofi SA
|
2.18% | -- | -- |
| Canadian Natural Resources Ltd | 2.17% | 70.40 | -2.03% |
|
Thales
|
2.17% | -- | -- |
Basic Info
| Investment Strategy | |
| The investment seeks long-term capital growth. The fund normally invests at least 40% of its assets in securities of foreign issuers. It may invest in foreign securities that are represented in the United States securities markets by American Depositary Receipts ("ADRs") or similar depository arrangements. The fund may invest in securities of issuers in emerging markets to a significant extent. The investment adviser takes environmental, social and governance ("ESG") factors into account in making investment decisions. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | CIGIX |
| Equity Style | Large Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | International Equity |
| Broad Category | Equity |
| Category Name | Foreign Large Growth |
| Category Index | MSCI ACWI Ex USA Growth NR USD |
| Prospectus Objective | Foreign Stock |
| Fund Owner Firm Name | Calamos |
| Prospectus Benchmark Index | |
| MSCI EAFE Growth NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSACXUSNTR | 100.0% |
| Manager Tenure | |
| John Calamos | 17.39 yrs |
| John Hillenbrand | 17.39 yrs |
| Jon Vacko | 17.39 yrs |
| Dennis Cogan | 9.42 yrs |
| Nick Niziolek | 9.42 yrs |
| Eli Pars | 7.42 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (8-12-22) | 0.01% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 15.43 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of June 30, 2022
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 3/16/2005 |
| Last Annual Report Date | 10/31/2021 |
| Last Prospectus Date | 3/1/2022 |
| Share Classes | |
| CIGCX | C |
| CIGIX | Inst |
| CIGOX | Retirement |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |